Psychedelic Medicine: Investing In The Psyk Etf

Horizons ETFs Management (Canada) Inc. launched the world's first psychedelics-focused ETF, the Horizons Psychedelic Stock Index ETF (PSYK), in January 2021. The ETF includes companies in the Canadian legal psychedelics industry, as well as U.S. companies engaged in legal activities involving psychedelic drugs and substances. The purpose of the ETF is to invest in, and indirectly derive revenues from, companies in the psychedelics industry engaged in legal activities involving psychedelic drugs and substances. The ETF will be managed by Horizons ETF Management and will be focused on the emerging psychedelics opportunity led by life science and pharmaceutical companies.

The ETF's purpose

The Horizons Psychedelic Stock Index ETF (PSYK) is the world's first exchange-traded fund focused on the emerging psychedelics opportunity led by life science and pharmaceutical companies. The ETF includes companies in the Canadian legal psychedelics industry, as well as U.S. companies engaged in legal activities involving psychedelic drugs and substances. The purpose of the ETF is to "invest in, and indirectly derive revenues from, companies in the psychedelics industry engaged in legal activities involving psychedelic drugs and substances."

The ETF will seek to replicate, to the extent possible and net of expenses, the performance of a market index that is designed to provide exposure to the performance of a basket of North American publicly-listed life sciences companies having significant business activities in, or significant exposure to, the psychedelics industry. PSYK will be using the North American Psychedelics Index as its market index. The Index is designed to provide a measure of the performance of North American publicly-listed life sciences companies focused on psychedelic medicines, and other companies with business activities in the psychedelics industry.

The Index has been designed to provide diversified exposure to the psychedelics industry and also to be adaptive to the evolution of the industry in a timely fashion. The underlying index is the North American Psychedelic Stock Index, provided by German-based index provider Solactive. Solactive AG will act as the independent calculation agent for the fund’s proprietary index.

The ETF will include a total of 17 North American life sciences companies, including Johnson & Johnson, COMPASS Pathways, Entheon Biomedical, Field Trip Health, Greenbrook TMS Inc, Havn Life Sciences, Mind Cure Health, Mydecine Innovations, Psyched Wellness, Red Light Holland, Revive Therapeutics, and Seelos Therapeutics.

Companies included in the ETF

The Horizons Psychedelic Stock Index ETF (PSYK) includes 17 North American life sciences companies that form part of the North American Psychedelics Index, provided by German index provider Solactive. The ETF includes companies in the Canadian legal psychedelics industry, as well as US companies engaged in legal activities involving psychedelic drugs and substances. The companies included in the ETF are:

• COMPASS Pathways (CMPS)
• Entheon Biomedical (ENBI)
• Field Trip Health (FTRP)
• Greenbrook TMS Inc (GTMS)
• Havn Life Sciences (HAVN)
• Johnson & Johnson (JNJ)
• Mind Cure Health (MCUR)
• Mydecine Innovations (MYCO)
• Psyched Wellness (PSYC)
• Red Light Holland (TRIP)
• Revive Therapeutics (RVV)
• Seelos Therapeutics (SEEL)
• Numinus Wellness (NUMI)
• MindMed (MMED)
• Nova Mentis (NOVA)
• Cybin Corp. (CYBN)

The ETF will seek to replicate the performance of a market index that is designed to provide exposure to the performance of a basket of North American publicly-listed life sciences companies with significant business activities in, or significant exposure to, the psychedelics industry.

ETF trading date and location

The Horizons Psychedelic Stock Index ETF (PSYK) is slated to begin trading on 27 January 2021, under the ticker symbol PSYK:NEO. It will trade on the Canadian NEO Exchange. The ETF will close its initial offering of units to its designated broker at the close of business on 26 January 2021, prior to its initial listing of units on NEO on 27 January 2021.

The ETF will include companies in the Canadian legal psychedelics industry, as well as US companies engaged in legal activities involving psychedelic drugs and substances.

For Americans, while the original listing is set to be in CAD, Horizons may also list on a US exchange under the ticker symbol PSYK.U.

ETF's management

The Horizons Psychedelic Stock Index ETF (PSYK) is the world's first exchange-traded fund focused on the emerging psychedelics opportunity led by life science and pharmaceutical companies. The ETF includes companies in the Canadian legal psychedelics industry, as well as U.S. companies engaged in legal activities involving psychedelic drugs and substances. The ETF will be managed by Horizons ETFs Management (Canada) Inc. and will be traded on the Canadian NEO Exchange under the ticker PSYK.

The purpose of the ETF is to "invest in, and indirectly derive revenues from, companies in the psychedelics industry engaged in legal activities involving psychedelic drugs and substances." The fund will seek to replicate the performance of a proprietary index of publicly listed companies that have significant business activities in or exposure to the psychedelics industry. This index is known as the North American Psychedelics Index, and it is provided by German index provider Solactive. Solactive AG will act as the independent calculation agent for the fund's proprietary index.

The ETF includes a total of 17 North American life sciences companies, which are:

• COMPASS Pathways (CMPS)
• Entheon Biomedical (ENBI)
• Field Trip Health (FTRP)
• Greenbrook TMS Inc (GTMS)
• Havn Life Sciences (HAVN)
• Johnson & Johnson (JNJ)
• Mind Cure Health (MCUR)
• Mydecine Innovations (MYCO)
• Psyched Wellness (PSYC)
• Red Light Holland (TRIP)
• Revive Therapeutics (RVV)
• Seelos Therapeutics (SEEL)

The ETF is expected to provide investors with exposure to the leading public companies undertaking research and development of treatments for mental illness, addiction, and eating disorders. This is possible due to recent policy changes and exemptions in Canada and the United States that have allowed for increased research into the therapeutic application of psychedelic compounds.

ETF's index

The Horizons Psychedelic Stock Index ETF (PSYK) is an exchange-traded fund (ETF) that focuses on the emerging psychedelics industry, led by life science and pharmaceutical companies. The ETF includes companies in the Canadian legal psychedelics industry, as well as U.S. companies engaged in legal activities involving psychedelic drugs and substances. The ETF's purpose is to "invest in, and indirectly derive revenues from, companies in the psychedelics industry engaged in legal activities involving psychedelic drugs and substances."

The underlying index for the Horizons Psychedelic ETF is the North American Psychedelic Stock Index, provided by German-based index provider Solactive. The index is designed to provide a measure of the performance of North American publicly-listed life sciences companies focused on psychedelic medicines and other companies with business activities in the psychedelics industry. The index has been created to provide diversified exposure to the psychedelics industry and adapt to the industry's evolution.

The Horizons Psychedelic ETF seeks to replicate the performance of a market index designed to provide exposure to a basket of North American publicly-listed life sciences companies with significant business activities in or exposure to the psychedelics industry. The ETF uses the North American Psychedelics Index as its market index, which is owned and operated by Horizons ETFs, with Solactive AG acting as the independent calculation agent.

The Horizons Psychedelic ETF includes a total of 17 North American life sciences companies, forming part of the North American Psychedelics Index. These companies include a mix of small but growing life sciences firms and global multinationals, such as Johnson & Johnson, which have developed in-market applications. The inclusion of these companies in the ETF provides investors with exposure to leading public companies undertaking critical research and development in the psychedelics space.

Frequently asked questions